Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study

  • Ocugen Inc OCGN announced results from the Phase 2/3 study of its COVID-19 vaccine candidate, COVAXIN.
  • COVAXIN has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein, whereas currently approved vaccines in the U.S. target only S-protein antigens. 
  • In contrast to other inactivated vaccines, trials have demonstrated that TLR7/8 agonist adjuvant in COVAXIN generates a Th1-biased immune response that induces robust long-term memory B- and T-cell responses.
  • Related: Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine.
  • Both co-primary immunogenicity endpoints were met well above the non-inferiority limit with robust immune responses.
  • Covaxin was found to be well-tolerated in vaccine-naïve individuals and individuals previously vaccinated with mRNA vaccines in the U.S., with no vaccine-related serious adverse events, thrombotic events, or cases of myocarditis or pericarditis.
  • Price Action: OCGN shares are up 20.8% at $1.57 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!